These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 27436163)

  • 1. A systematic review of the benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic kidney disease.
    Kamiya H
    Hemodial Int; 2017 Jan; 21(1):72-83. PubMed ID: 27436163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Dipeptidyl Peptidase-4 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Bae JH; Kim S; Park EG; Kim SG; Hahn S; Kim NH
    Endocrinol Metab (Seoul); 2019 Mar; 34(1):80-92. PubMed ID: 30912341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy and safety of dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus patients with severe renal impairment: a meta-analysis.
    Chen M; Liu Y; Jin J; He Q
    Ren Fail; 2016; 38(4):581-7. PubMed ID: 26915531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
    Yang M; Wang L; Gu L; Yuan W
    J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials.
    Walker SR; Komenda P; Khojah S; Al-Tuwaijri W; MacDonald K; Hiebert B; Tangri N; Nadurak SWD; Ferguson TW; Rigatto C; Tangri N
    Nephron; 2017; 136(2):85-94. PubMed ID: 28178698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
    Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
    Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
    Abe M; Okada K
    Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
    Mikhail N
    Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
    Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
    Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials.
    Li R; Wang R; Li H; Sun S; Zou M; Cheng G
    Diabetes Metab Res Rev; 2016 Sep; 32(6):460-9. PubMed ID: 26433213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis.
    Gor D; Lee TA; Schumock GT; Walton SM; Gerber BS; Nutescu EA; Touchette DR
    J Manag Care Spec Pharm; 2020 Jan; 26(1):67-75. PubMed ID: 31880221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitus.
    Kaneko M; Narukawa M
    Diabetes Res Clin Pract; 2016 Jun; 116():171-82. PubMed ID: 27321333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
    Xu S; Zhang X; Tang L; Zhang F; Tong N
    Postgrad Med; 2017 Mar; 129(2):205-215. PubMed ID: 27813442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis.
    Salvo F; Moore N; Arnaud M; Robinson P; Raschi E; De Ponti F; Bégaud B; Pariente A
    BMJ; 2016 May; 353():i2231. PubMed ID: 27142267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with moderate to severe renal impairment: a systematic review and meta-analysis.
    Cheng D; Fei Y; Liu Y; Li J; Chen Y; Wang X; Wang N
    PLoS One; 2014; 9(10):e111543. PubMed ID: 25360775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies.
    Li L; Li S; Deng K; Liu J; Vandvik PO; Zhao P; Zhang L; Shen J; Bala MM; Sohani ZN; Wong E; Busse JW; Ebrahim S; Malaga G; Rios LP; Wang Y; Chen Q; Guyatt GH; Sun X
    BMJ; 2016 Feb; 352():i610. PubMed ID: 26888822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
    O'Hara DV; Parkhill TR; Badve SV; Jun M; Jardine MJ; Perkovic V
    Diabetes Obes Metab; 2021 Mar; 23(3):763-773. PubMed ID: 33269512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
    Penno G; Garofolo M; Del Prato S
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
    Wu S; Chai S; Yang J; Cai T; Xu Y; Yang Z; Zhang Y; Ji L; Sun F; Zhan S
    Clin Ther; 2017 Sep; 39(9):1780-1789.e33. PubMed ID: 28827024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.